<SEC-DOCUMENT>0001171843-21-004300.txt : 20210614
<SEC-HEADER>0001171843-21-004300.hdr.sgml : 20210614
<ACCEPTANCE-DATETIME>20210614063009
ACCESSION NUMBER:		0001171843-21-004300
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210614
FILED AS OF DATE:		20210614
DATE AS OF CHANGE:		20210614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		211013265

	BUSINESS ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_061421.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong>Date of report:&#160;</strong><strong>For the month of June 2021</strong></p><p style="text-align: center;"><strong>Commission File Number: 001-39084</strong></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Innate Pharma S.A.</strong></font><br />(Translation of registrant's name into English)</p><p style="text-align: center;"><strong>Innate Pharma S.A.<br />117 Avenue de Luminy&#8212;BP 30191<br />13009 Marseille, France <br />+ 33 (0) 4 30 30 30 &#160;</strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p><p>Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </p><p align="center"><strong>INCORPORATION BY REFERENCE</strong></p><p>This Report on Form&#160;6-K and Exhibit 99.1 to this Report on Form&#160;6-K shall be deemed to be incorporated by reference into the registration statement on Form&#160;F-3&#160;(File&#160;No.&#160;333-252074)&#160;of Innate Pharma S.A. (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.</p><hr style="page-break-after: always;" noshade="noshade" /><p> <p style="text-align: center;"><font style="font-size: 10pt;"><strong>EXHIBIT INDEX</strong></font></p><p style="text-align: center;"><font style="font-size: 10pt;">&#160;</font></p><table style="font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"><tr><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;"><strong>Exhibit</strong></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;"><strong>Description</strong></font></td></tr><tr><td>&#160;</td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;">&#160;</font></td></tr><tr><td><font style="font-size: 10pt;"><a href="exh_991.htm">99.1</a></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;"><a href="exh_991.htm">Press Release dated June 14, 2021</a> </font></td></tr></table></p><p /><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURES</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td>&#160;</td><td>&#160;</td><td style="text-transform: uppercase;" colspan="2"><strong>Innate Pharma S.A.</strong></td></tr><tr valign="top"><td style="width: 47%;">&#160;</td><td style="width: 6%;">&#160;</td><td style="text-align: center; width: 10%;">&#160;</td><td style="text-align: center; width: 84%;">&#160;</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td colspan="2"></td></tr><tr valign="top"><td>Date: June 14, 2021</td><td>&#160;</td><td>By:</td><td style="border-bottom: black 1pt solid;">/s/ Laure-H&#233;l&#232;ne Mercier&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td>Name:&#160;&#160;&#160;&#160;&#160;</td><td>Laure-H&#233;l&#232;ne Mercier</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td>Title:</td><td>Chief Financial Officer</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td colspan="2"></td></tr></table></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>Number of Shares and Voting Rights of Innate Pharma as of June 1, 2021</strong></font></p><p style="text-align: center;"><strong></strong></p><p>
 <p align="justify">MARSEILLE, France, June  14, 2021  (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French &#8220;Code de Commerce&#8221; and the article 223-16 of the French stock-market authorities (<em>Autorit&#233; des March&#233;s Financiers</em>, or &#8220;<strong>AMF</strong>&#8221;) General Regulation, Innate Pharma SA (the &#8220;<strong>Company</strong>&#8221; - Euronext Paris: FR0010331421 &#8211; IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as of June 1, 2021:<br ><br ></p> <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:50%; width:50%; min-width:50%;;text-align: justify ;  vertical-align: middle; ">Total number of shares outstanding:</td><td style="max-width:50%; width:50%; min-width:50%;;text-align: justify ;  vertical-align: middle; ">79,027,540 ordinary shares</td></tr><tr><td style="text-align: justify ;  vertical-align: middle; ">&#160;</td><td style="text-align: justify ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: justify ;  vertical-align: middle; ">&#160;</td><td style="text-align: justify ;  vertical-align: middle; ">6,796 Preferred Shares 2016 <br ></td></tr><tr><td style="text-align: justify ;  vertical-align: middle; ">&#160;</td><td style="text-align: justify ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: justify ;  vertical-align: middle; ">&#160;</td><td style="text-align: justify ;  vertical-align: middle; ">7,581 Preferred Shares 2017<br ></td></tr><tr><td style="text-align: justify ;  vertical-align: middle; ">&#160;</td><td style="text-align: justify ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: justify ;  vertical-align: middle; ">Total number of theoretical voting rights (1):<br ></td><td style="text-align: justify ;  vertical-align: middle; ">79,822,040 <br ></td></tr><tr><td style="text-align: justify ;  vertical-align: middle; ">&#160;</td><td style="text-align: justify ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: justify ;  vertical-align: middle; ">Total number of exercisable voting rights (2):</td><td style="text-align: justify ;  vertical-align: middle; ">79,803,465</td></tr></table> <p align="justify"><em><br >(1) The total number of theoretical voting rights (or &#8220;gross&#8221; voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016 (2016 Preferred Shares), i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2.</em></p>  <p align="justify"><em>(2) The total number of exercisable voting rights (or &#8220;net&#8221; voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.</em></p>  <p align="justify"><strong>About Innate Pharma:</strong></p>  <p align="justify">Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.</p>  <p align="justify">Innate Pharma&#8217;s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.</p>  <p align="justify">Innate is a pioneer in the understanding of Natural Killer (NK) cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.</p>  <p align="justify">Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.</p>  <p align="justify">Learn more about Innate Pharma at&#160;www.innate-pharma.com</p>  <p align="justify"><strong>Information about Innate Pharma shares:</strong></p> <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="text-align: left ;  vertical-align: middle; "><strong>ISIN code</strong> <br > <strong>Ticker code</strong> <br > <strong>LEI</strong></td><td style="text-align: justify ;  vertical-align: middle; ">FR0010331421 <br > Euronext: IPH Nasdaq: IPHA <br > 9695002Y8420ZB8HJE29</td></tr></table> <p align="justify"><strong>Disclaimer on forward-looking information and risk factors: </strong></p>  <p align="justify">This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;expect&#8221; and &#8220;will&#8221; and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company&#8217;s commercialization efforts, the Company&#8217;s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company&#8217;s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (&#8220;Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (&#8220;AMF&#8221;), which is available on the AMF website http://www.amf-france.org or on Innate Pharma&#8217;s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), including the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2020, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.</p>  <p align="justify">This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.</p> <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td colspan="3" style="text-align: justify ;  vertical-align: middle; "><strong>For additional information, please contact:</strong></td></tr><tr><td colspan="3" style="text-align: justify ;  vertical-align: middle; ">&#160;</td></tr><tr><td style="text-align: justify ;  vertical-align: middle; vertical-align: top ; "><strong><u>Investors</u></strong> <br ><br > <strong>Innate Pharma </strong> <br > Tel.: +33 (0)4 30 30 30 30 <br > <u>i</u><u>nvestors@innate-pharma.com</u></td><td style="text-align: justify ;  vertical-align: middle; ">&#160;</td><td style="text-align: justify ;  vertical-align: middle; "><strong><u>Media</u></strong> <br ><br > <strong>Innate Pharma </strong> <br > Tracy Rossin (Global/US) <br > Tel.: +1 240 801 0076 <br > <u>Tracy.Rossin@innate-pharma.com</u> <br ><br > <strong>ATCG Press </strong> <br > Marie Puvieux (France) <br > Tel.: +33 (0)9 81 87 46 72 <br > <u>innate-pharma@atcg-partners.com</u></td></tr></table> <p>&#160;<br ></p> </p><p ></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
